Beautiful Gothenburg, Sweden is hosting EWMA 2019 - the European Wound Management Association conference, on June 5-9.

Gothenburg, Sweden's second largest city after Stockholm, located on the coast in southwestern Sweden, is considered "the quintessential 'second city': understatedly hip and unexpectedly vibrant with neoclassical architecture lining its tram-rattled streets, locals sunning themselves beside canals, and always an interesting cultural or social event going on."

Here are some of SmartTRAK's top things to do when taking a break from the conference. And we know what we're talking about - SmartTRAK's Senior Analyst, Advanced Wound Care, Lennart Stadler lives there!

IRVINE, CALIF. (PRWEB) MAY 13, 2019

BioMedGPS is excited to host its subscribers and guests on Tuesday, June 4th, at a very special Pre-EWMA 2019 event at Gothenburg’s Universeum Aquarium.

SmartTRAK’s Advanced Wound Care Experts will serve as panelists. Susan Paquette - SmartTRAK VP & General Manager, Wound - will be providing overall insights on the wound market and Lennart Stadler - SmartTRAK Senior Analyst, Advanced Wound Care - will be presenting data on important trends and innovations.

SmartTRAK, the leading source of competitive intelligence used by the top ten global orthopedic & wound care companies, was cited as a source in 3M's presentation "3M to Acquire Acelity Inc." published on May 2.

#SAWC2019 in San Antonio is fantastic! So many things to do and see. Stay tuned for articles from SmartTRAK with updates and highlights. In the meantime, a few photos!

SmartTRAK talks with Raoul Verheggen, Global Product Director for DSM Biomedical, regarding the Company’s recent foray into the wound care space and how its addressing unmet needs for patients and businesses

Novel materials and components are key to innovative wound care products that provide superior patient outcomes. DSM Biomedical is a B2B supplier whose business it is to provide these unique components to the medical device industry. SmartTRAK talks with Raoul Verheggen of DSM Biomedical, Global Product Director for Wound, about the company, their capabilities and plans moving forward in support of wound care. A transcript of the interview is below. To listen to the interview recorded via Uberconference, click on the following video. 

SmartTRAK highlights the latest research on Sigvaris SECURE presented at SAWC Fall

A novel hybrid compression garment offers promise for patients with difficult-to-treat chronic edema according to an 11-patient case series presented at SAWC Fall. Patients with chronic edema, including lymphedema, are challenged in finding compression garments that are clinically efficacious, cosmetically appealing and comfortable to wear. The 11-patient case series evaluated Sigvaris’ recently launched SECURE, an innovative new Compression and Containment Hybrid (CCH) garment that combines the comfort of circular knit garments and the stiffness traditionally provided by thicker textiles, inelastic wraps or flat knit garments. The new hybrid circular knit garments are thin, cosmetically appealing, and meet the clinical requirement of chronic edema management – graduated compression and containment.

Dressings recover Q418, all segments showing solid gains

For FY18, according to BioMedGPS’ SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenues for Advanced Dressings, External Devices and Biologics were up +4.1% YoY. Acelity remains the global market leader followed by S&N and Mölnlycke. Advanced Dressings, the workhorse of Advanced Wound Care, accounts for 52.3% of WW revenues, up +3.3% YoY. Skin/Dermal Substitute (CTP) revenue was up +10.7% YoY, lower than previous years, but still double-digit gains. WW NPWT was up +4.3% YoY, with traditional devices having a slight uptick and single-use driving the increase of +28.9%.

Among the many topics covered in the Q418/FY18 Advanced Wound Care Market Recap are:

S&N plans to shore up its Advanced Wound Bioactives business with the acquisition of Osiris Therapeutics but the deal may be in question as Osiris shareholders challenge the price.

 Smith & Nephew (S&N) announced on March 12, 2019 that it has agreed to acquire Osiris Therapeutics for $660MM with the deal expected to close Q219. However, the deal could be in question as a group of Osiris shareholders is suing to block the acquisition. The lawsuit disputes Cantor Fitzgerald’s discounted cash flow analysis, saying it does not adequately reflect Osiris’s future growth prospects, and is based on growth rates that are about half of what Osiris has experienced in recent years, resulting in a valuation that is too low. The acquisition would add the Osiris’s Grafix and Stravix product lines to S&N’s ailing Advanced Wound Bioactives portfolio. If allowed to proceed, the acquisition would solidify S&N’s leadership in wound biologics and changes the competitive landscape in the Advanced Wound Care market.

The US market for Hemostats and Sealants accelerated in Q418 driven by growth in fibrin sealants and thrombin hemostats, overcoming slow growth during the first half of the year.

The US market for Hemostats and Sealants accelerated with +9.3% YoY growth in Q418, continuing to build on its +7.9% YoY in Q318, with fibrin sealants and thrombin hemostats driving the increase. The US market grew +6.1% in FY18, overcoming slow growth during the first half of the year.

As reported in SmartTRAK Financial Dashboard, every manufacturer in the Hemostats and Sealants market, except Pfizer and CryoLife, experienced revenue growth in Q418. Leading the way was Baxter with +33.1% YoY growth as it made progress with its integration of the Mallinckrodt portfolio. Ethicon and Becton Dickinson (BD) both posted solid gains, with +8.7% YoY and +6.6% YoY growth, respectively...

SmartTRAK was cited as a source in a press release from Smith & Nephew entitled "Smith & Nephew expands in high growth regenerative medicine market through acquisition of Osiris Therapeutics, Inc."